Applied DNA - Multiplikator Forward P/S APDN
Applied DNA Sciences (APDN) profitability remains low due to high capital burn associated with product promotion. The company's projected P/S reflects market expectations, where 2.20 determines the latest valuation metric. Long-term contracts for cargo anti-counterfeiting and the implementation of automated AI platforms for DNA synthesis, which minimize production defects, provide positive catalysts.
Ringkesan rincian data analitis Applied DNA Corp (APDN)
- rega pasar lan target rega analis:
- rincian nilai pasar emiten:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Applied DNA Sciences|APDN - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Applied DNA Sciences|APDN - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Applied DNA Corp|APDN - Utang jangka dawa|Utang jangka cendhak perusahaan Applied DNA Sciences|Rasio cepet adnas.com
- indikator pendapatan resik lan kelipatan nilai:
APDN - Penghasilan resik|Proyeksi bathi mangsa ngarep Applied DNA Sciences|APDN - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Applied DNA|APDN - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Applied DNA Corp|APDN - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Applied DNA Sciences|APDN - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan adnas.com|APDN - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Applied DNA Sciences
- statistik dodolan lan pendapatan perusahaan:
Analisis komprehensif perusahaan:Applied DNA Sciences, Inc. APDN
Forward P/S links current market capitalization to expected revenue, allowing an investor to assess the value of one dollar of projected sales. An analysis of the forward P/S for Applied DNA Sciences (APDN) reveals whether the asset is overbought or undervalued, which is critical for Applied DNA Sciences (APDN), as its scalability through automated DNA marking and synthesis robotics must translate into exponential growth in future revenues.
Analisis pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|QGEN: Kapitalisasi marang prakiraan pendapatan|Ionis Pharma - Multiplikator Forward P/S|RGEN - Multiplikator Forward P/S|RNA (Avidity Biosciences) - Multiplikator forward rega marang pendapatan|crisprtx.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan GeneDx|Ultragenyx Pharmaceutical Inc. (RARE) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S BEAM|Multiplikator forward rega marang pendapatan Sarepta Corp SRPT|Multiplikator Forward P/S TWST (Twist Bioscience)|Rasio kapitalisasi marang dodolan sing dikarepake 10xgenomics.com (TXG)|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stoke Therapeutics Inc|BioLife Corp (BLFS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan WVE|MAZE (Maze Therapeutics Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan sionnatx.com (SION)|Multiplikator Forward P/S PRME|TSHA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|Rasio kapitalisasi marang dodolan sing dikarepake MeiraGTx Corp (MGTX)|REGENXBIO Inc. - Multiplikator Forward P/S|SLDB - Multiplikator Forward P/S|Ocugen (OCGN) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan PACB (Pacific Biosciences of California, Inc.)|BNTC (Benitec) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Corp)|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S LXEO (Lexeo Therapeutics, Inc.)|KRRO: Kapitalisasi marang prakiraan pendapatan|EDIT - Rasio rega marang prakiraan pendapatan|SLN (Silence Therapeutics Corp) - Kapitalisasi marang prakiraan pendapatan|PRQR: Multiplikator Forward P/S|Codexis (CDXS) - Multiplikator Forward P/S|SGMO (Sangamo Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Nautilus Biotechnology Inc|Rasio rega marang prakiraan pendapatan Metagenomi, Inc (MGX)|DTIL: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Generation Bio GBIO|BOLD (boundlessbio.com) - Rega mangsa ngarep marang pendapatan|XCUR - Rasio rega marang prakiraan pendapatan|IMNN: Rasio rega marang prakiraan pendapatan|PHIO: Multiplikator Forward P/S|MBIO - Rasio kapitalisasi marang dodolan sing dikarepake|RNAZ (TransCode Therapeutics Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Bionano BNGO|Multiplikator Forward P/S BLUE|immunoprecise.com - Kapitalisasi marang prakiraan pendapatan|Omega - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan OMIC|Regulus Therapeutics - Multiplikator Forward P/S|SYRS (syros.com) - Kapitalisasi marang prakiraan pendapatan|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TCON|UBX (Unity Bio) - Multiplikator Forward P/S
